SCHEMBL2422976

SCHEMBL2422976

CC(C)(C)OC(=O)N1CCN(c2ccnc3ccccc23)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.55
GBA1 P04062 2/20 0.54
IDE P14735 2/20 0.53
ACHE P22303 2/20 0.53
ADRB2 P07550 1/20 0.52
NCF1 P14598 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
CKS1B P61024 2/20 0.51
SKP1 P63208 2/20 0.51
SKP2 Q13309 2/20 0.51
AKT1 P31749 1/20 0.51
GPR119 Q8TDV5 2/20 0.50
POLB P06746 1/20 0.49
CLK1 P49759 1/20 0.49
DRD2 P14416 1/20 0.48
DRD3 P35462 1/20 0.48
KIT P10721 1/20 0.48
SMARCA2 P51531 1/20 0.48
SMARCA4 P51532 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369080 0.91 POLB (0.54) PDGFRBGBA1IDEACHEMEN1
SCHEMBL30059059 0.87 ALDH1A1 (0.52) PDGFRBGBA1IDEMEN1KMT2A
SCHEMBL30059071 0.87 ALDH1A1 (0.52) PDGFRBGBA1IDEMEN1KMT2A
SCHEMBL30059046 0.87 ALDH1A1 (0.52) PDGFRBGBA1IDEMEN1KMT2A
SCHEMBL23362105 0.85 MAPK1 (0.54) PDGFRBGBA1IDEMEN1KMT2A
SCHEMBL23362929 0.85 MAPK1 (0.54) PDGFRBGBA1IDEMEN1KMT2A
SCHEMBL30060432 0.85 MAPK1 (0.54) PDGFRBGBA1IDEMEN1KMT2A
SCHEMBL23362102 0.85 MAPK1 (0.54) PDGFRBGBA1IDEMEN1KMT2A
SCHEMBL900183 0.85 IDE (0.71) PDGFRBIDEADRB2NCF1MEN1
SCHEMBL30060970 0.85 PDGFRB (0.57) PDGFRBIDEADRB2NCF1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026241-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2011-09-27 US disclosed
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility UNIVERSITA DEGLI STUDI DI SIENA (IT) 2009-09-24 US disclosed
US-7582761-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-09-01 US disclosed
US-20090143575-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS BALAN CHENERA 2009-06-04 US disclosed
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 US disclosed
EP-1551811-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS Amgen Inc. (US) 2005-07-13 EP disclosed
US-20040152690-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2004-08-05 US disclosed
WO-2004035549-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS AMGEN INC. (US) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143575-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV3, TRPV2 PDGFRB 192/4885GBA1 1859/4885IDE 3884/4885
US-20040152690-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV3, TRPV2 PDGFRB 216/4885GBA1 2163/4885IDE 3864/4885
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility HTR2C, HTR2A, DRD2 PDGFRB 563/4885GBA1 2277/4885IDE 2594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.